Chemoprevention of cutaneous squamous cell carcinoma and its precursors in solid organ transplant recipients using topical sirolimus: A randomized, double-blind, placebo-controlled pilot trial

Abstract

To the Editor: Immunosuppression in solid organ transplant recipients (SOTR) greatly increases the risk of keratinocyte cancer (KC), indisputably a significant burden in terms of morbidity, mortality, and cost. Switching calcineurin inhibitors to sirolimus is a major strategy that has resulted in a two-fold reduction in the risk of squamous cell carcinomas (SCC) but is poorly tolerated with many serious adverse events.1,2